July 23, 2026
JDCA is excited to announce the publication of our Half-Year Practical Cure Portfolio Review! The portfolio features a collection of 44 companies tracked by JDCA that are researching one or more components of a Practical Cure for T1D. Today, it remains the only publication assessing companies for both their financial strength and potential T1D impact.
In recent years, T1D research has progressed meaningfully, with advancements in cell supply and protection methods spurring excitement. This progress has led to increasing activity from for-profits, investing more resources, attention, and capital from entities both large and small. Moving forward, it is important to fully evaluate the for-profit players that could bring a cure to market, as, ultimately, all Practical Cure solutions will pass through commercial hands to reach the finish line.
In recent years, T1D research has progressed meaningfully, with advancements in cell supply and protection methods spurring excitement. This progress has led to increasing activity from for-profits, investing more resources, attention, and capital from entities both large and small. Moving forward, it is important to fully evaluate the for-profit players that could bring a cure to market, as, ultimately, all Practical Cure solutions will pass through commercial hands to reach the finish line.
Tracked companies range from fledgling startups to well-established leaders in the pharmaceutical arena, testing across both animal models and human clinical trials.
All have real cure potential.
All have real cure potential.
Highlights
- Financial Performance: Analysis of 44 companies developing a cell supply, cell protection, or full Practical Cure solution for T1D.
- Research Progress: At-a-glance insight into the research pathway and development stage of each company.
- Upcoming News: Anticipated research and financial milestones in the second half of 2026.
- Detailed infographics: Clear visuals summarizing each company's potential impact on T1D.
- Ranked Performance: Analysis of the top and bottom-performing companies in 1H26.
Note: JDCA's Practical Cure Portfolio differs from the Practical Cure list, a separate but related tracker. While our Practical Cure list focuses on complete cure solutions in clinical trials (by academic and for-profit institutions), the Practical Cure Portfolio takes a broader look at the overall market.
